TY - JOUR
T1 - Macrophage-derived foam cells in atherosclerosis
T2 - Lessons from murine models and implications for therapy
AU - Webb, Nancy R.
AU - Moore, Kathryn J.
PY - 2007/12
Y1 - 2007/12
N2 - Macrophage-derived foam cells play integral roles in all stages of atherosclerosis. These lipid-laden immune cells are present from the earliest discernable fatty-streak lesions to advanced plaques, and are key regulators of the pathologic behavior of plaques. This review summarizes the current understanding of the molecular mechanisms that regulate macrophage cholesterol uptake, foam cell formation, and lipid-driven pro-inflammatory responses that promote atherosclerosis. Specific emphasis will be placed on recent findings from mouse models of atherosclerosis regarding the pathways of macrophage differentiation into foam cells and their implications for developing macrophage-directed therapeutic targets.
AB - Macrophage-derived foam cells play integral roles in all stages of atherosclerosis. These lipid-laden immune cells are present from the earliest discernable fatty-streak lesions to advanced plaques, and are key regulators of the pathologic behavior of plaques. This review summarizes the current understanding of the molecular mechanisms that regulate macrophage cholesterol uptake, foam cell formation, and lipid-driven pro-inflammatory responses that promote atherosclerosis. Specific emphasis will be placed on recent findings from mouse models of atherosclerosis regarding the pathways of macrophage differentiation into foam cells and their implications for developing macrophage-directed therapeutic targets.
KW - Macrophage foam cell
KW - Modified lipoprotein
KW - Oxidation
KW - Scavenger receptor
KW - Secretory phospholipase A2
UR - https://www.scopus.com/pages/publications/38349132245
UR - https://www.scopus.com/inward/citedby.url?scp=38349132245&partnerID=8YFLogxK
U2 - 10.2174/138945007783220597
DO - 10.2174/138945007783220597
M3 - Review article
C2 - 18220702
AN - SCOPUS:38349132245
SN - 1389-4501
VL - 8
SP - 1249
EP - 1263
JO - Current Drug Targets
JF - Current Drug Targets
IS - 12
ER -